“One should not be part of anything below Rs 400-crore turnover. One must have a very good reason why it has to be in the portfolio unless they belong to auto ancillary and specialty chemical and specialty pharma segments., ” says Ajay Srivastava.
“I expect midcap indices to be more volatile both on the upside as well as downside. Among large caps, some of the new companies will probably take over from some of the older names in the Nifty in the next one year.”